BindingDB logo
myBDB logout

33 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
24909677 19 Lead identification of benzimidazolone and azabenzimidazolone arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists.EBI GlaxoSmithKline Medicines Research Centre
24090135 201 Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.EBI Sanofi
23437772 35 Colloidal aggregation causes inhibition of G protein-coupled receptors.EBI University of North Carolina Chapel Hill School of Medicine
20627722 89 Identification of a sulfonamide series of CCR2 antagonists.EBI GlaxoSmithKline Medicines Research Centre
22546204 9 Recent developments and biological activities of thiazolidinone derivatives: a review.EBI Dr. Hari Singh Gour University
23079519 86 In vivo activity of an azole series of CCR2 antagonists.EBI GlaxoSmithKline Research and Development
22931505 69 Chemokine receptor antagonists.EBI National Heart and Lung Institute
22437117 47 Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation.EBI GlaxoSmithKline Medicines Research Centre
22047688 51 CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood.EBI GlaxoSmithKline
21341682 37 Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.EBI Telik, Inc.
20297846 33 Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.EBI Genzyme Corp.
19674898 31 Spiropiperidine CCR5 antagonists.EBI Roche Palo Alto LLC
20099827 34 Discovery and optimization of novel 3-piperazinylcoumarin antagonist of chemokine-like factor 1 with oral antiasthma activity in mice.EBI Chinese Academy of Medical Sciences and Peking Union Medical College
19081254 33 Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines.EBI Astellas Pharma Inc.
19014885 32 Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.EBI Roche Palo Alto LLC
18694645 25 Potent CCR4 antagonists: synthesis, evaluation, and docking study of 2,4-diaminoquinazolines.EBI Astellas Pharma Inc.
18539035 20 Discovery of potent CCR4 antagonists: Synthesis and structure-activity relationship study of 2,4-diaminoquinazolines.EBI Astellas Pharma Inc.
17395464 38 Small molecule antagonists of the CC chemokine receptor 4 (CCR4).EBI Millennium Pharmaceuticals
17098428 21 Core exploration in optimization of chemokine receptor CCR4 antagonists.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16698264 37 Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.EBI Merck Research Laboratories
16539392 29 Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.EBI Takeda Pharmaceutical Company Limited
16497499 36 Optimization of 2-aminothiazole derivatives as CCR4 antagonists.EBI Amgen Inc.
16236499 17 Optimization of CCR4 antagonists: side-chain exploration.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15863339 29 Identification of chemokine receptor CCR4 antagonist.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15026036 91 Discovery and SAR of trisubstituted thiazolidinones as CCR4 antagonists.EBI Array BioPharma
11720852 51 Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.EBI Merck Research Laboratories
11720851 52 Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.EBI Merck Research Laboratories
11311066 76 Design, synthesis, and discovery of a novel CCR1 antagonist.EBI Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories
11206474 51 Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.EBI Merck Research Laboratories
10821717 29 Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.EBI Takeda Chemical Industries, Ltd.
17718722 30 Bipiperidinyl carboxylic acid amides as potent, selective, and functionally active CCR4 antagonists.BDB Pfizer